SoftOx Solutions AS (OSL:SOFTX)
Norway · Delayed Price · Currency is NOK 0.1060
+0.0016 (1.53%)
At close: Apr 24, 2026
SoftOx Solutions AS Earnings Call Transcripts
Fiscal Year 2025
-
A stabilized hypochlorous acid inhalation solution is advancing to a Phase 2a proof-of-concept study in cystic fibrosis, targeting robust bacterial load reduction as a key milestone. Significant market opportunities exist in CF and NCFB, supported by a flexible equity facility and a focus on attracting pharma partners by 2027.
Fiscal Year 2024
-
A new management team will lead a lean, project-focused organization, prioritizing a Phase II trial for ventilator-associated pneumonia with strong preclinical and Phase I data. Funding efforts target NOK 60-80 million, with industrial partnerships sought post-trial.